Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Zhang, Jian Ying; Megliorino, Roxanne; Peng, Xuan; Tan, Eng M.; Chen, Yao; Chan, Edward K. L.

doi:10.1016/j.jhep.2006.08.010

Cited by 87 publications

(121 citation statements)

References 36 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Koziol et al (2003) used five anti-TAA antibodies to acquire 79% sensitivity and 86% specificity, which are equivalent to those of Wang. In addition, different types of cancer showed distinct profiles of autoantibody in which specific TAAs were preferentially targeted Koziol et al, 2003;Zhang et al, 2007).These studies support the hypothesis that ''customized" TAA arrays enhance autoantibody detection in cancer and constitute promising and powerful tools for the immunoserological diagnosis of certain types of cancer, such as breast, liver and prostate cancer.…”

Section: Discussionmentioning

confidence: 72%

Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer

Qin

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Sera of cancer patients may contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs). The present study aimed to determine whether a mini-array of multiple TAAs would enhance antibody detection and be a useful approach in esophageal cancer detection and diagnosis. Our mini-array of multiple TAAs consisted of eleven antigens, p53, pl6, Impl, CyclinB1, C-myc, RalA, p62, Survivin, Koc, CyclinD1 and CyclinE full-length recombinant proteins. Enzyme-linked immunosorbent assays (ELISA) were used to detect autoantibodies against eleven selected TAAs in 174 sera from patients with esophageal cancer, as well as 242 sera from normal individuals. In addition, positive results of ELISA were confirmed by Western blotting. In a parallel screening trial, with the successive addition of antigen to a final total of eleven TAAs, there was a stepwise increase in positive antibody reactions. The eleven TAAs were the best parallel combination, and the sensitivity and specificity in diagnosing esophageal cancer was 75.3% and 81.0%, respectively. The positive and negative predictive values were 74.0% and 82.0%, respectively, indicating that the parallel assay of eleven TAAs raised the diagnostic precision significantly. In addition, the levels of antibodies to seven antigens, comprising p53, Impl, C-myc, RalA, p62, Survivin, and CyclinD1, were significantly different in various stages of esophageal cancer, which showed that autoantibodies may be involved in the pathogenesis and progression of esophageal cancer. All in all, this study further supports our previous hypothesis that a combination of antibodies might acquire higher sensitivity for the diagnosis of certain types of cancer. A customized miniarray of multiple carefully-selected TAAs is able to enhance autoantibody detection in the immunodiagnosis of esophageal cancer and autoantibodies to TAAs might be reference indicators of clinical stage.

show abstract

Section: Discussionmentioning

confidence: 72%

Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer

Qin

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…Zhang et al (21) reported that the positive ratio of the survivin antibody was 11.3% (16/142) in patients with HCC and 2.4% (2/82) in heathy controls (capture antibody, goat anti-human immunoglobulin G (IgG); Caltag Laboratories, Burlingame, CA, USA). However, the study failed to identify the autoantibody in the serum of the patients with cirrhosis and chronic hepatitis using the ELISA assays (21).…”

Section: Discussionmentioning

confidence: 99%

Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

Abstract. Survivin expression in the serum of patients with hepatocellular carcinoma (HCC) and nonmalignant chronic liver diseases remain to be elucidated. The aims of the present study were to evaluate the diagnostic role of survivin in the serum of patients with HCC and identify which ELISA kit performed best in detecting the levels of serum survivin. In total, 80 patients were included in the present study, including 20 patients with HCC, 20 patients with liver cirrhosis, 20 patients with chronic hepatitis B virus infection and 20 healthy volunteers. The levels of survivin protein in the serum were detected using two different ELISA kits (R&D and Abnova). The positive ratios of serum survivin detected by the R&D ELISA kit in all the cases were 8.75% (7/80; median, 0 pg/ml; range, 0-39.8 pg/ml) and in HCC patients were 5% (1/20; median, 0 pg/ml; range, 0-39.8 pg/ml). For the same samples analyzed using the Abnova ELISA kit, the positive ratios of serum survivin in all the cases were 22.5% (18/80; median, 0 pg/ml; range, 0-553.5 pg/ml) and in HCC patients were 25% (5/20; median, 0 pg/ml; range, 0-93.5 pg/ml). The results obtained by the different ELISA kits demonstrated no statistically significant differences in the level of survivin between HCC patients and healthy controls. The correlation coefficient was 0.0064 (P= 0.481) when analyzing the same serum samples with the different ELISA kits. In addition, the highest positive ratio of serum survivin was observed using the Abnova kit. A statistically significant difference in the results was observed between the R&D and Abnova kits. In general, the levels and positive ratios of serum survivin in the patients with HCC were significantly low. Furthermore, no difference was observed between HCC patients and controls in regard to the levels of serum survivin detected by the R&D and Abnova ELISA kits. In conclusion, survivin is unlikely to be a promising serological maker for the diagnosis of HCC. IntroductionHepatocellular carcinoma (HCC) is the sixth most common malignant neoplasm and the third most common cause of cancer-associated mortalities worldwide (1,2). At present, the combination of α-fetoprotein (AFP) with ultrasonography or computed tomography (CT) is widely used in clinical practice for the early diagnosis of HCC. However, a previous study identified that the sensitivity of AFP was only 25-65%. In addition, a number of patients with chronic hepatitis, liver cirrhosis and other liver diseases or gastrointestinal cancers have been found to exhibit elevated levels of AFP (3). Therefore, identifying novel and promising makers that may improve the diagnostic accuracy of HCC is required. Survivin, also known as baculoviral inhibitor of apoptosis repeat containing 5 (BIRC 5), is an inhibition of apoptosis protein. It was initially separated by researchers from Yale University, and has since been identified to be involved in the inhibition of apoptosis (4) and the regulation of mitosis (5).Previous studies have revealed that survivin is highly expressed in the...

show abstract

“…With the successive addition of TAAs to a final total of eight antigens, there was a stepwise increase of positive antibody reactions up to 59.9%, which was significantly higher than the frequency of antibodies in chronic hepatitis (20%), liver cirrhosis (30%) and normal individuals (12.2%). The sensitivity in diagnosing HCC was 59.9%, and the specificity was 87.8%, 80.0% and 70.0%, respectively, compared to normal individuals, chronic hepatitis and liver cirrhosis cases (34). This study further demonstrates that malignant transition in HCC is associated with autoantibody responses to certain cellular proteins which might have a role in tumorigenesis, and suggests that a mini-array of eight TAAs may enhance antibody detection for diagnosis of HCC.…”

Section: Using a Mini-array Of Multiple Taas To Enhance Antibody Detementioning

confidence: 65%

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Zhang¹

2007

Autoimmunity Reviews

Self Cite

View full text Add to dashboard Cite

Liver cancer, especially hepatocellular carcinoma (HCC), is particularly prevalent in Africa and Asia. HCC affects the Hispanic population of the United States at a rate double that of the white population. The majority of people with HCC will die within 1 year of its detection. This high case-fatality rate can in part be attributed to lack of diagnostic methods that allow early detection. How to establish a methodology to identify the high-risk individuals for HCC remains to be investigated. The multifactorial and multi-step nature in the molecular pathogenesis of human cancers must be taken into account in both the design and interpretation of studies to identify markers which will be useful for early detection of cancer. Our recent studies demonstrated that a mini-array of multiple tumorassociated antigens (TAAs) might enhance autoantibody detection for diagnosis of HCC, especially for the alpha fetoprotein (AFP)-negative cases. It also suggested that different types of cancer might require different panels of TAAs to achieve the sensitivity and specificity required to make immunodiagnosis a feasible adjunct to tumor diagnosis.

show abstract

Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Cited by 87 publications

References 36 publications

Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer

Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer

Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Contact Info

Product

Resources

About